Search results
Results from the WOW.Com Content Network
Cryoprecipitate, also called cryo for short, or Cryoprecipitate Antihemophilic factor (AHF), is a frozen blood product prepared from blood plasma. [1] To create cryoprecipitate, Plasma is slowly thawed to 1–6 °C. A cold-insoluble precipitate is formed, which is collected by centrifugation, resuspended in a small amount of residual plasma ...
The term cryosupernatant (also called cryo-poor plasma, cryoprecipitate depleted, cryoprecipitate reduced plasma) refers to plasma from which the cryoprecipitate has been removed. It is used to treat thrombocytopenic purpura .
The continuous-flow preparation of cryoprecipitate was subsequently integrated into the process upstream of Cohn Fractionation. [ 13 ] Nevertheless, this process still serves as a major foundation for the blood industry in general and its influence can be seen as it is referred to in the development of newer methods.
Fresh frozen plasma (FFP) is a blood product made from the liquid portion of whole blood. [3] It is used to treat conditions in which there are low blood clotting factors (INR > 1.5) or low levels of other blood proteins. [3] [1] It may also be used as the replacement fluid in plasma exchange.
Thromboelastography (TEG) is a method of testing the efficiency of blood coagulation.It is a test mainly used in surgery and anesthesiology, although increasingly used in resuscitations in emergency departments, intensive care units, and labor and delivery suites.
Cryofibrinogenemia refers to a condition classified as a fibrinogen disorder in which a person's blood plasma is allowed to cool substantially (i.e. from its normal temperature of 37 °C to the near-freezing temperature of 4 °C), causing the (reversible) precipitation of a complex containing fibrinogen, fibrin, fibronectin, and, occasionally, small amounts of fibrin split products, albumin ...
Thrombin is an enzyme that splits fibrinogen into fibrin monomers in 10 to 60 seconds, which aggregate to form a three-dimensional gel-like structure. Thrombin also activates factor XIII from the human body to factor XIIIa, which then cross-links the fibrin monomers to form a stable clot. Both these processes need calcium to work.
Acute-phase proteins, particularly fibrinogen, interact with sialic acid on the surface of RBCs to facilitate the formation of rouleaux. An increase in the ratio of RBCs to plasma volume, as seen in the setting of polycythemia and hypovolemia, decreases rouleaux formation and decreases sedimentation.